Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME6VX4)

Drug Name

GZ402668 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cambridge pathology 1 antigen (CD52)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alemtuzumab	DMZL3IV	Acute myelogenous leukaemia	2A41	Approved	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cambridge pathology 1 antigen (CD52)	TTQT5S9	CD52_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02282826) A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis. U.S. National Institutes of Health.
2	Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14.
3	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49.